<ul data-eligibleForWebStory="true"><li>Over 80% of traditional clinical trials fail to meet enrolment targets due to protocol design not aligning with patients' lifestyles.</li><li>Biotech startups often neglect to consider patient realities in trial design, leading to low participation rates, especially in underserved populations.</li><li>Decentralized trials are on the rise, but startups must not overlook the importance of establishing trust and human connections alongside technology.</li><li>Operational oversights, rigidity in trial structures, and confusing compliance with engagement can hinder the success of clinical trials for biotech startups.</li></ul>

What Biotech Startups Get Wrong About Clinical Trials

Discover more